Background and aims: Hepatic concentrations of the powerful vasoconstrictor and fibrogen endothelin 1 (ET-1) and its receptors increase in human and experimental cirrhosis, suggesting a major role for ET-1 in the pathology of chronic liver disease. We investigated whether ET-1 receptor antagonism, after the development of fibrosis and cirrhosis, arrests/reverses the progression of chronic liver disease. Methods: Chronic liver injury was induced in rats by carbon tetrachloride (CCl 4 ) treatment (0.15 ml/kg intraperitoneally twice a week) in conjunction with phenobarbital in drinking water (0.4 g/l) for four (group 1: fibrosis) and eight (group 2: cirrhosis) weeks. Rat were then treated concurrently with the ET-1 receptor antagonist TAK-044 (10 mg/kg/day) and CCl 4 /phenobarbital for a further four weeks. Results: Histopathological examination revealed significant arrest of progression to cirrhosis in group 1 and reversal of cirrhosis in group 2 rats. TAK-044 treatment caused significant amelioration of portal hypertension, systemic hypotension, and liver injury (reduced activities of serum aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase), and improved hepatic synthetic capacity (increased serum albumin concentration) in both groups of rats relative to vehicle treated rats. TAK-044 treatment reduced collagen synthesis, as evidenced by decreased hepatic hydroxyproline content, mRNA expression of collagen-a type I, and tissue inhibitors of matrix metalloproteinases 1 and 2, and mRNA and protein expression of a potent fibrogenic cytokine, transforming growth factor b1.
T he causative mechanisms of liver cirrhosis and associated portal hypertension have been investigated extensively in the hope of developing more effective pharmacological and surgical therapies. Endothelin 1 (ET-1) is the most potent constrictor of the hepatic vasculature, 1 and has been implicated in fibrotic remodelling of major organs. [2] [3] [4] [5] Hepatic concentrations of ET-1 and its receptors increase in human [6] [7] [8] and experimental 9 10 cirrhosis. Furthermore, ET-1 increases circulating and hepatic levels of the potent hypotensive agent platelet activating factor (PAF) in cirrhosis, 11 12 perhaps contributing to systemic hypotension.
Of the two main ET-1 receptor subtypes, ET A on vascular smooth muscle cells causes vasoconstriction while ET B on endothelial cells normally causes vasorelaxation via nitric oxide (NO). Interestingly, ET B stimulation appears to play a major role in hepatic vasoconstriction 1 13 with the pure ET B agonist sarafotoxin S6c causing a greater increase in portal pressure in cirrhotic rats than in control rats. 14 15 Moreover, ET-1 elicits contraction of perisinusoidal stellate cells via both receptor subtypes 7 16 and stimulates the synthesis of transforming growth factor b (TGF-b) and collagen via ET A and ET B receptors, respectively. 17 Collectively, these findings strongly suggest that ET-1, by acting via both receptor subtypes, is an integral part of the structural and haemodynamic abnormalities of liver cirrhosis.
Carbon tetrachloride (CCl 4 ) induced cirrhosis in rats, which exhibits several characteristics of human liver disease, including excessive fibrosis with uniform micronodular transformation, portal hypertension, ascites, and hyperdynamic circulation, [18] [19] [20] has been used extensively to investigate the biochemical and molecular mechanisms of the development and complications of cirrhosis. An ET A antagonist LU135252 was found to ameliorate experimental biliary fibrosis but caused significant mortality due to its renal toxicity, particularly when the dose of the antagonist was increased. 21 Other studies reported that ET A antagonism does not affect portal hypertension in cirrhotic rats 22 and worsens hepatic microcirculatory changes and necrosis in endotoxin treated rats. 23 On the other hand, portal administration of the ET B agonist sarafotoxin S6c exacerbates portal hypertension. 15 However, short term portal infusion of ET A +ET B antagonists in cirrhotic rats reduces portal hypertension, 10 14 24 and antagonism of both receptors ameliorates endotoxin induced liver injury. 25 It is not known if long term antagonism of both receptors can be used in treating fibrosis and portal hypertension without eliciting toxic effects. Recently, we found that spontaneous resolution of CCl 4 induced cirrhosis was accelerated by treatment with a mixed ET A +ET B antagonist TAK-044 (cyclo(D-a-aspartyl-3-((-4-phenylpiperazin-1-yl)carbonyl)L-alanyl-L-a-aspartyl-D-2-(2-thienyl)glycyl-L-Leucyl-D-tryptophyl)disodium salt). 26 In the present study, we show that long term treatment with TAK-044 concurrent with chronic CCl 4 treatment not only arrests the progression of fibrosis to cirrhosis but also reverses cirrhosis without eliciting toxic effects.
Abbreviations: ET, endothelin; MAP, mean arterial pressure; MMP, matrix metalloproteinase; NO, nitric oxide; PAF, platelet activating factor; SMA, smooth muscle actin; TGF, transforming growth factor; TIMP, tissue inhibitors of metalloproteinases; CCl 4 , carbon tetrachloride; TGF-b, transforming growth factor b; c-GT, c-glutamyl transferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; RT-PCR, reverse transcriptase-polymerase chain reaction; QRT-PCR, quantitative real time PCR; ECM, extracellular matrix
MATERIALS AND METHODS

Induction of liver cirrhosis
The experimental protocols were approved by the University of Pittsburgh Institutional Animal Care and Use Committee according to the guidelines of the National Institutes of Health. Chronic liver injury was induced in male SpragueDawley rats (230-250 g), as described previously, 9 10 by CCl 4 administration (0.15 ml/kg intraperitoneally twice a week) in conjunction with phenobarbital (0.4 g/l) in drinking water. Control rats received injection of the carrier (peanut oil) and phenobarbital water. At the end of four weeks of treatment, femoral arterial and portal venous pressures were measured in three control and three CCl 4 treated rats, as described previously. 10 25 26 Briefly, under pentobarbital anaesthesia, a PE-50 catheter was inserted into the femoral artery to monitor arterial blood pressure. The hepatic trigone was exposed via laparotomy and the portal vein was skeletonised. The intestines and abdominal cavity were covered with warm saline soaked sponges during the entire experimental period. A 23 gauge needle in a PE-50 catheter was inserted into the portal vein to measure portal pressure. After stable recordings of arterial and portal venous pressure, blood was drawn from the femoral artery. The liver was excised, washed in ice cold phosphate buffered saline, and snap frozen in liquid nitrogen, after storing a slice of left lateral lobe in 10% buffered formalin.
The remaining CCl 4 treated rats were randomly distributed into two groups. In one group, Alzet osmotic minipumps containing saline or a solution of TAK-044 were inserted into the peritoneal cavity via a small incision in the abdomen. Fifty per cent each of the CCl 4 treated rats received TAK-044 (10 mg/kg/day) or saline, while continuing CCl 4 treatment. At the end of eight weeks livers of seven saline+CCl 4 treated, seven TAK-044+CCl 4 treated, and three control rats were processed as described above, after blood pressure measurements and blood withdrawal.
In the other group of CCl 4 treated rats, the above procedure was repeated at the end of eight weeks; seven saline+CCl 4 treated, seven TAK-044+CCl 4 treated, and three control rats were used at the end of 12 weeks.
Determination of ET-1 and its receptors ET-1 was extracted and its concentration measured by ELISA (Peninsula Laboratories, Sunnyvale, California, USA). Hepatic ET-1 receptors were determined by saturation and competition binding assays, essentially as described previously. 6 9 25 Biochemical parameters Serum total protein, albumin, bilirubin, c-glutamyl transferase (c-GT), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were estimated using a kit from Stanbio Laboratory (Boerne, Texas, USA).
Morphology and scoring of liver cirrhosis
Sections of 4 mm thickness were prepared from formalin fixed liver slices embedded in paraffin and stained with haematoxylin-eosin and Masson's trichrome stain. 27 Liver pathology was graded by VMS in a blinded manner using an established scoring system, as described previously 26 ; a score of ''5'' was considered as complete cirrhosis and ''0'' as normal. Sections were also treated with anti-a-smooth muscle actin (SMA) antibody (Dako, Carpinteria, California, USA; smooth muscle actin-1A4) to determine activated stellate cells/myofibroblasts, 28 as described previously. 26 29 Determination of RNA expression Relative mRNA expressions of preproET-1, ET-1 receptors, collagen a type I, and TGF-b1 were determined by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR), essentially as described previously. 26 The same amount of cDNA was used to determine expression of b-actin mRNA for normalisation. The number of PCR cycles employed was in the linear range of the reaction for each product.
Quantitative real time PCR (QRT-PCR) was performed for mRNA expression of tissue inhibitors of metalloproteinases (TIMPs) using a Prism 7700 Sequence Detector from Applied Biosystems Inc. (ABI, Foster City, California, USA) with data acquisition and analysis by Sequence Detector software v. 1.7a. Assay of cDNA levels was performed using Taqman Universal Master Mix (ABI) and the primer probe sets from Invitrogen (Rockville, Maryland, USA). Primers were designed using Primer Express software (ABI). Threshold cycle numbers were determined for TIMP-1 and TIMP-2 and corrected using the equivalent data for b-actin.
Determination of hydroxyproline and collagenase
Hepatic hydoxyproline content was measured as described previously using the chloramine T/p-dimethylaminobenzaldehyde procedure. 26 30 For determination of collagenase, the liver was homogenised in 0.3 M Tris HCl buffer (pH 7.4) and centrifuged at 200 rpm for five minutes. Enzyme activity was determined in the supernatant with an assay kit from Chemicon International Inc (Temecula, California, USA) which measures matrix degrading metalloproteinases (MMP)-1, MMP-8, and MMP-13, but not gelatinases (MMP-2).
Determination of TGF-b1
The liver was homogenised in 2.5 N acetic acid containing 10 M urea, 100 mg/ml PMSF, and 10 mg/ml pepstatin, and incubated for 20 minutes at room temperature in polypropylene tubes. After neutralisation with 2.7 N NaOH in 1 M HEPES, the homogenate was centrifuged at 20 190 g for 20 minutes. TGF-b1 content was determined in the supernatant by ELISA (Promega, Madison, Wisconsin, USA).
Statistical analysis
Results are expressed as mean (SEM). Physiological, histopathological, and biochemical findings represent averages of seven rats (CCl 4 or CCl 4 +TAK-044 treatment) and three rats (control) for each time point. Results of molecular assays represent averages of samples from at least three rats in each group, each analysed in duplicate or triplicate. Statistical significance was derived by the non-parametric MannWhitney two tailed variance test using the SPSS program to determine significance between multiple groups. A p value of ,0.05 was considered statistically significant.
RESULTS
Endothelin and its receptors
Hepatic concentrations of ET-1 increased by threefold, fourfold, and sevenfold, respectively, after 4, 8, and 12 weeks of CCl 4 treatment ( fig 1A) ; similar increases were also observed in the preproET-1 mRNA transcript (figs 1B, 2A). ET-1 concentration was 40% and 20% less in TAK-044 treated rats than in saline treated rats at eight and 12 weeks, respectively.
ET A receptor density increased by 40%, 60%, and 80% after 4, 8, and 12 weeks of CCl 4 treatment, respectively ( fig 3A) . ET B receptor density increased by 1.5-fold at four weeks, and by 3. General characteristics (table 1) The body weight of CCl 4 treated rats was 25%, 20%, and 30% lower than that of paired controls at 4, 8, and 12 weeks, respectively. TAK-044 treatment of rats receiving CCl 4 improved body weight by 5% and 23%, respectively, at eight and 12 weeks. The weight of the spleen increased significantly after eight and 12 weeks of CCl 4 treatment; TAK-044 prevented the increase in spleen weight at eight weeks to a small extent but not at 12 weeks. All of the CCl 4 treated rats developed ascites at eight and 12 weeks; the volume of ascites was nearly eight times greater at 12 weeks than at eight weeks of CCl 4 treatment. TAK-044 treatment caused 50% and 75% reduction in ascites at eight and 12 weeks, respectively. The synthetic capacity of the liver was reduced in CCl 4 treated rats, as indicated by decreased serum albumin, which was normalised by TAK-044 treatment. Liver injury, as estimated by serum LDH, AST, ALT, and c-GT, also improved significantly in TAK-044 treated rats.
No mortality occurred in TAK-044+CCl 4 treated rats, and mortality was less than 5% in saline+CCl 4 treated rats at eight and 12 weeks of treatment. Figure 4A shows normal hepatic architecture in control rats. Liver fibrosis was evident, with the beginning of septum formation after four weeks of CCl 4 treatment ( fig 4B) . In control livers, a-SMA positive cells were present in portal veins and hepatic arteries ( fig 5A) but staining of cells in 4D) and decreased the number of a-SMA positive cells in the fibrous areas ( fig 5D) . At 12 weeks, the pathological score and fibrosis were similar to that after eight weeks of CCl 4 treatment although the fibrous bands were relatively thicker ( fig 4E) . A substantial number of a-SMA positive cells were observed at the interface between hepatocytes and the fibrous tissue and inside the parenchyma after 12 weeks of CCl 4 treatment ( fig 5E) . Interestingly, however, the number of a-SMA positive cells in the middle of fibrous tissue was reduced after 12 weeks of CCl 4 treatment compared to that at eight weeks. TAK-044 treatment between eight and 12 weeks caused marked reduction of fibrosis ( fig 4F) which was associated with marked reduction in the number a-SMA positive cells ( fig 5F v fig 5E) . A summary of the histopathology scores depicted in a bar graph (fig 6) shows significant amelioration of the pathology by TAK-044 after both eight weeks and 12 weeks of CCl 4 treatment.
Histological assessment
Collagen mRNA, hydroxyproline, collagenase, and TIMP mRNA mRNA expression of collagen a type I increased respectively by 4, 9, and 13-fold at 4, 8, and 12 weeks of CCl 4 treatment (fig 7) . mRNA expression of collagen I in rats treated concurrently with TAK-044 and CCl 4 was 50% less than in saline+CCl 4 treated rats at both eight and 12 weeks (fig 7) . CCl 4 treatment increased hepatic hydroxyproline by twofold at four weeks and by 10-fold at eight and 12 weeks (fig 8) . A significant (35%) reduction in hydroxyproline occurred in rats receiving TAK-044 relative to those receiving saline between four and eight weeks as well as eight and 12 weeks of CCl 4 treatment.
Hepatic collagenase activity increased by 64% at four weeks and by twofold at eight and 12 weeks of CCl 4 treatment (fig 9) . Concurrent TAK-044 and CCl 4 treatment caused 30% and 20% decreases in collagenase activity at eight and 12 weeks, respectively (fig 9) .
Matrix metalloproteinases (MMPs) are important in liver fibrogenesis and its resolution but we were unable to obtain any conclusive evidence for changes in expression of MMP-1 and MMP-13 in CCl 4 and TAK-044+CCl 4 treated rat livers (not shown). TIMP-1 and TIMP-2 modulate fibrosis by inhibiting MMPs. [31] [32] [33] QRT-PCR demonstrated 33%, 300%, and 150% increases in TIMP-1 mRNA, and 65%, 260%, and 310% increases in TIMP-2 mRNA after 4, 8, and 12 weeks of CCl 4 treatment, respectively (fig 10) . TAK-044 reduced mRNA expression of TIMP-1 by 36% and 65%, and of TIMP-2 by 34% and 22% at eight and 12 weeks, respectively.
TGF-b1
Hepatic TGF-b1 content increased respectively by 0.8, 8, and 11-fold at 4, 8, and 12 weeks of CCl 4 treatment ( fig 11A) . TAK-044 caused nearly 60% reduction in TGF-b1 content at both eight and 12 weeks relative to saline treated rats. Increased hepatic mRNA expression of TGF-b1 in CCl 4 treated rats (which was similarly increased at 4, 8, and 12 weeks) also decreased on treatment with TAK-044 ( fig 11B, 11C) .
Mean arterial and portal venous pressure
Mean arterial pressure (MAP) was not significantly different between control and CCl 4 treated rats at four weeks ( fig 12A) . At both eight and 12 weeks of CCl 4 treatment, MAP decreased by nearly 30% compared with paired controls. Between four and eight weeks of concurrent TAK-044 treatment, MAP tended to rise but the change did not reach statistical significance. On the other hand, significant improvement (almost to normal levels) in MAP occurred on TAK-044 treatment between eight and 12 weeks ( fig 12A) . Portal venous pressure increased significantly in rats treated with CCl 4 for eight and 12 weeks (100-150% increase), indicative of portal hypertension ( fig 12B) . In both groups, TAK-044 reduced portal hypertension remarkably, with portal pressure being only 30-50% higher than in control rats.
DISCUSSION
The profound haemodynamic and metabolic effects of ET-1 in the normal liver, 1 34 35 progressive increase in the ET-1 system from initiation of CCl 4 induced liver injury to development of cirrhosis, 10 and upregulation of the ET-1 system in experimental biliary cirrhosis 36 and human cirrhosis of various aetiologies [6] [7] [8] indicate that ET-1 is a major factor in the pathogenesis and complications of the chronic liver disease. The ET-1 receptor antagonist TAK-044 accelerates the spontaneous reversal of CCl 4 induced cirrhosis in rats. 26 The present investigation demonstrates that administration of TAK-044 concurrent with CCl 4 arrests progression of fibrosis to cirrhosis and reverses cirrhosis.
Activated hepatic stellate cells and portal myofibroblasts accumulating in fibrous areas are primarily responsible for excessive deposition of extracellular matrix (ECM) components and architectural distortion 37 38 ; both cell types express a-SMA. We observed a-SMA positive cells both within the fibrous septa and at the interphase between the parenchyma and fibrous tissue at four and eight weeks of CCl 4 treatment. In the wide fibrous septa, observed at 12 weeks of CCl 4 treatment, a-SMA positive cells were found predominantly at the interphase, and a substantial number within the parenchyma. With increased deposition of the ECM, cells likely migrate to the outer region of the fibrous tissue. Rats treated with TAK-044 had substantially decreased numbers of a-SMA positive cells and fibrous tissue deposition, morphological findings concordant with the beneficial effects of the inhibitor.
ET-1 likely mediates hepatic fibrogenesis by stimulating the synthesis of and/or by influencing the activities of mediators such as TGF-b, platelet derived growth factor, and tumour necrosis factor a, 17 39 40 all of which can cause activation, proliferation, and fibrogenesis in stellate cells. 37 mRNA and protein expression of the powerful fibrogenic cytokine TGF-b1 was reduced in TAK-044 treated rats. Type I collagen is a major component of the ECM deposited in liver fibrosis, 41 42 and TAK-044 both prevented the increase in collagen a type I mRNA expression during CCl 4 treatment between four and eight weeks, and reduced its expression remarkably at 12 weeks. TAK-044 also caused marked reduction in hepatic hydroxyproline content. Together, these results suggest that ET-1 plays an important role in fibrogenesis by modulating TGF-b1 and collagen synthesis. However, such effects of ET-1 may be indirect as ET-1 stimulates synthesis of collagen and TGF-b1 in normal but not in activated stellate cells. 17 Increased deposition of collagen in the fibrotic liver is a result of its enhanced synthesis and reduced degradation. Paradoxically, hepatic collagenase activity measured in vitro is significantly increased in CCl 4 treated rats (present study, and also Okazaki and Maruyama 43 and Montfort and PerezTamayo 44 ) and decreased by TAK-044 treatment. Either collagen synthesis far exceeds its degradation or collagenase activity measured in vitro is strongly suppressed in vivo by TIMPs which are increased in the fibrotic liver. 45 The rapid decrease in TIMP expression seen during spontaneous recovery from CCl 4 induced advanced fibrosis 46 likely increases collagenase activity in vivo, reversing ECM deposition. This is consistent with our finding of decreased TIMP-1 and TIMP-2 expression in rats receiving TAK-044.
The present 58% and 60% decreases in portal hypertension in TAK-044 treated rats at eight and 12 weeks, respectively, are combinations of the resolution of fibrosis and inhibition of the contractile component. Acute infusion of TAK-044 in cirrhotic rats affects only the contractile component, 10 giving a more modest (20%) decrease in portal hypertension. Both ET-1 receptor subtypes appear to be critical in the haemodynamic component of portal hypertension, with sinusoidal and presinusoidal constriction caused by ET A and ET B receptors, respectively. 13 Mixed ET A +ET B antagonists reduce portal hypertension in cirrhotic rats 10 24 47 but do not affect portal pressure in normal rats. 10 24 Thus the haemodynamic component of portal hypertension in cirrhosis includes major participation of the upregulated ET A and ET B receptors, and increased endogenous ET-1.
Decreased MAP in cirrhosis is attributed to increased production of several vasodilatory mediators, including NO and PAF. 48 49 In the present study, MAP was found to increase in rats treated with TAK-044. Therefore, inability of the acute treatment with ET-1 receptor antagonist to improve systemic hypotension 10 suggests requirement of long term antagonism of ET-1 receptors in the liver, and possibly in the systemic vasculature. As ET A antagonist is unable to alter arterial pressure in cirrhotic rats, 22 our results also suggest that ET B plays a primary role in systemic hypotension in cirrhosis. Indeed, ET B has been shown to stimulate the synthesis of NO and PAF, respectively, in endothelial cells 50 and Kupffer cells 51 ; the latter effect is augmented in cirrhosis. 11 ET A , on the other hand, seems to limit systemic hypotension as intraarterial infusion of the ET A antagonist BQ-123 caused a greater increase in forearm blood flow in cirrhotic patients compared with normal volunteers. 52 Cirrhosis causes upregulation of the hepatic ET-1 system in both rats and humans. 6-10 22 36 Both ET A and ET B receptors appear to play important roles in the development and complications of cirrhosis, and review of the literature suggests that simultaneous antagonism of both receptor subtypes is necessary to achieve beneficial effects. Rockey and Chung 14 found that essentially concurrent administration of the mixed antagonist bosentan and CCl 4 (bosentan from day 0, CCl 4 from day 2) significantly decreased hepatic collagen mRNA (stellate cells) and protein (liver section) at day 22. This short term (,3 week) study also showed that bosentan inhibited activation (measured as a-SMA expression) of stellate cells. In contrast, a long term experiment 53 used CCl 4 /phenobarbital from week 0 and RO48-5695, a mixed ET A /ET B inhibitor optimised from bosentan, from week 8. At week 17, cirrhotic rats had significantly elevated ALT, c-GT, bilirubin, portal pressure, and significantly decreased MAP and serum proteins. Hepatic histology also showed cirrhotic changes. However, there was no significant normalisation of any parameter with RO 48-5695 treatment.
The effectiveness of RO 48-5695 in vivo has been demonstrated in experimental models of hypercholesterolaemia, 54 55 and inflammatory bowel disease and gastric ulcerogenesis 56 57 but RO 48-5695 is also ineffective in the reduced renal mass model of glomerular sclerosis. 58 Obviously, a comparative study of TAK-044 and RO 48-5695 in cirrhosis would be of interest.
In summary, simultaneous antagonism of both ET-1 receptor subtypes slows the progression of fibrosis to cirrhosis, and reverses cirrhosis. In addition, TAK-044 can reduce portal hypertension and systemic hypotension, major complications that are almost always present in cirrhosis. These observations, and the similarity between the changes in the hepatic ET-1 system in human and experimental cirrhosis, suggest that mixed ET A /ET B antagonists such as TAK-044 have strong therapeutic potential in chronic liver disease.
EDITOR'S QUIZ: GI SNAPSHOT Answer
From question on page 1000
During menses, colonoscopy showed a large multilobulate polyp (3.5 cm in diameter) of the sigmoid colon with a hyperaemic and friable mucosa (fig 1) . Histological examination showed a normal mucosa with the presence of some branched crypts and marked inflammation in the lamina propria.
During the intermenstrual period (on the eighth day of the cycle), polyp size had decreased; its surface appeared only slightly lobulate without friability and with hyperaemia, which was reduced at two red spots (fig 2) . Histopathological evaluation showed the presence of endometriotic foci in the context of a mucosa containing branched crypts.
The patient was submitted to a gynaecological examination which was found to be normal. Pelvic and vaginal ultrasounds did not show evidence of endometriotic lesions. Magnetic resonance imaging detected a 1.8 cm area with a T1 hyperintense and T2 hypointense signal in the sigmoid wall.
Medical treatment with leuprolide acetate depot, a gonadotropin releasing hormone agonist (GnRH-a) (3.75 mg intramuscularly every four weeks for three months) was started. Abdominal pain and bloody diarrhoea promptly disappeared. At the four month follow up she was still free of symptoms and anaemia had reversed (haemoglobin 12.3 g/dl). At the one year follow up, colonoscopy showed a flat lesion without hyperaemia or friability at the site of the endometriotic polyp. Histological examination of multiple biopsies was normal and a magnetic resonance imaging showed complete disappearance of the previously detected lesion. After 18 months of follow up, the patient remains completely asymptomatic.
Endometriosis is defined as the presence of endometrial tissue in sites other than the uterus. The rectosigmoid is the most frequently involved site. Heterotopic endometrium generally adheres to serosal surfaces and may invade the bowel wall. However, appearance as a polyp is rarely reported. Infiltration of the mucosa is uncommon and therefore the endoscopic biopsy may not be diagnostic. The variable appearance on endoscopy is related to the cyclic endometrial tissue changes.
Surgical resection is indicated for massive rectal bleeding or obstruction but the role of surgery is less clear when the clinical course is not life threatening. Medical treatment with a GnRH-a is commonly used in pelvic endometriosis but studies on its efficacy in intestinal endometriosis are still lacking.
To our knowledge this is the first case reported in the literature showing that an endometriotic colonic polyp may be successfully treated by medical therapy with a GnRH-a. This case further illustrates that endometriosis may appear as a colonic polyp and that polypectomy is not curative.
